key: cord-0788272-jrb81ol1
authors: Chouchana, Laurent; Preta, Laure-Hélène; Tisseyre, Mylène; Terrier, Benjamin; Treluyer, Jean-Marc; Montastruc, François
title: Kidney Disorders as Serious Adverse Drug Reactions of Remdesivir in Covid-19: A Retrospective Case-Non case Study
date: 2021-02-26
journal: Kidney Int
DOI: 10.1016/j.kint.2021.02.015
sha: 176df3e6d4f9eeb5b1855ab4712ce2197e7e8aab
doc_id: 788272
cord_uid: jrb81ol1

nan

approved for coronavirus disease 2019 (Covid-19), albeit an uncertain clinical relevance. In clinical trials and case series, acute kidney injury (AKI), including renal replacement, have been frequently reported. 1, 2 Although causality is debatable, kidney injuries especially proximal tubular epithelial cell necrosis have also been observed in animal studies during remdesivir development.

In order to provide additional information, we performed a pharmacovigilance analysis on the WHO global database of individual case safety reports (ICSRs), VigiBase (https://www.who-umc.org/vigibase/vigibase/). This database gathers spontaneous reports of suspected adverse drug reactions (ADR) from more than 130 countries, which makes it a very powerful tool to perform disproportionality analyses. 3 This approach, based on a case-noncase method, estimates whether an adverse event is differentially reported for a specific drug compared with other drugs. Among 1,565,117 reports registered until August 30 th 2020, 5,532 concerned Covid-19 patients and have been included in this study. Of them, 434 (7.8%) cases were related to kidney disorders, including 327 (5.9%) reported with remdesivir. In remdesivir kidney disorder cases, 217 (66.3%) patients were male with a median age of 65 (IQR, 55-73) years (Suppl Table 1 ). Remdesivir was early discontinued with a median treatment duration of 3 (IQR, 1-4) days. In the vast majority of cases (316, 96.6%), no other drug was suspected in the onset of kidney disorders. Reactions were serious in 301 (92.0%) cases, with a fatal outcome for 15 (4.6%) patients. They were mainly AKI in 295 (90.2%) cases and tubular necrosis in 8 (2.4%) cases.

Compared to the use of chloroquine, hydroxychloroquine, dexamethasone, sarilumab or tocilizumab, the use of remdesivir was associated with an increased reporting of kidney disorders (ROR, 7.2; CI 95% 5.7-9.0) ( Table 1) Our findings, based on post-marketing real-life data from more than 5,000 Covid-19 patients, support that kidney disorders, almost exclusively AKI, represent a serious, early and potentially fatal ADR of remdesivir. These results are consistent with findings from another group. 4 Physicians should be aware of this potential risk and perform close kidney monitoring when prescribing remdesivir. Further data are needed to confirm that safety signal. J o u r n a l P r e -p r o o f * Kidney disorder cases were individual case safety reports containing any reaction belonging to the kidney system as system organ class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA, https://www.meddra.org/). ** Non cases were reports containing any other reaction.

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Case report study of the first five COVID-19 patients treated with remdesivir in France

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database